The study recruited 105 lung cancer patients who had previously received at least one line of platinum-based treatment; over half of the patients had received prior programmed death ligand (PD-L1) inhibitors (55%), and nearly half had received multikinase inhibitors (48%). Here, CD274 is linked to lung carcinoma.